Susvimo® (ranibizumab) – New indication
May 21, 2025 - Roche announced the FDA approval of Susvimo (ranibizumab), for the treatment of patients with diabetic retinopathy (DR) who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor medication.
Top